|1.||Ishizaka, Akitoshi: 5 articles (10/2011 - 01/2004)|
|2.||Kawabata, Kazuhito: 5 articles (12/2008 - 05/2002)|
|3.||Aikawa, Naoki: 4 articles (01/2014 - 01/2004)|
|4.||Izumikawa, Koichi: 4 articles (10/2010 - 03/2007)|
|5.||Kohno, Shigeru: 4 articles (10/2010 - 03/2007)|
|6.||Yanagihara, Katsunori: 4 articles (10/2010 - 03/2007)|
|7.||Seki, Masafumi: 4 articles (10/2010 - 03/2007)|
|8.||Matsuoka, Shozo: 4 articles (01/2005 - 05/2002)|
|9.||Suda, Koichi: 3 articles (09/2013 - 05/2010)|
|10.||Miyasho, Taku: 3 articles (09/2013 - 05/2010)|
09/01/2014 - "In contrast, Sivelestat treatment significantly ameliorated the LPS-induced lung injury, as judged by the marked improvement in all these indices. "
02/01/2007 - "In contrast, sivelestat treatment significantly ameliorated the HSR-induced lung injury, as judged by the marked improvement in all these indices. "
01/01/2010 - "The lung injury scores and Pa(O2)/Fl(O2) ratio of the sivelestat group were significantly more severe than those of the control group from days 1 to 4. On day 5, the lung injury score and Pa(O2)/Fl(O2) ratio of the sivelestat group improved to the same levels of those of the control group. "
10/01/2001 - "Our study clearly indicates that posttreatment with NEI reduces neutrophil activation in the pulmonary vessels and neutrophil accumulation in the lungs and suggests that ONO-5046, even when administered after the primary intestinal insult, can prevent the progression of lung injury associated with intestinal I/R."
09/01/2014 - "Improving effect of Sivelestat on lipopolysaccharide-induced lung injury in rats."
|2.||Acute Lung Injury
12/01/2008 - "The present study was designed to examine whether inhibition of NE activity by sivelestat, a specific NE inhibitor with low cellular permeability, is beneficial for acute lung injury induced by Streptococcus pneumoniae in hamsters. "
06/01/2006 - "These results suggest the possibility of conducting prospective clinical trials to assess the efficacy of early sivelestat-Na therapy for aspiration-related acute lung injury."
06/01/2006 - "The efficacy of sivelestat-Na on aspiration-related acute lung injury was analyzed by reviewing case reports published before or after the appearance of the drug on the clinical practice in Japan. "
04/01/2010 - "The impact of oxidative stress levels on the clinical effectiveness of sivelestat in treating acute lung injury: an electron spin resonance study."
08/01/2008 - "The aim of this study was to evaluate the effect of sivelestat and to determine whether it can reduce lipopolysaccharide (LPS)-induced acute lung injury in rats. "
|3.||Systemic Inflammatory Response Syndrome (Sepsis Syndrome)
01/01/2009 - "Sivelestat has been reported to be effective for ALI associated with systemic inflammatory response syndrome (SIRS), but the effectiveness and safety of the drug for infants has not been confirmed. "
08/01/2003 - "Clinical studies have demonstrated that Sivelestat improves this injury that is associated with systemic inflammatory response syndrome. "
05/01/2002 - "In a trial of ALI patients with systemic inflammatory response syndrome, conducted in Japan by Ono Pharmaceutical scientists, sivelestat treatment improved the investigator assessment of global improvement and the percentages of patients who were removed from ventilators and transferred out of the intensive care unit. "
07/01/2011 - "Sivelestat improved oxygenation in the postoperative period; however, there were no differences between the two groups in terms of duration of mechanical ventilation, intensive care unit stay, systemic inflammatory response syndrome, and postoperative change of oxygenation. "
01/01/2013 - "Sivelestat has been used clinically to treat acute lung injury associated with systemic inflammatory response syndrome. "
12/01/2013 - "In the present study, we investigated the protective effects of sivelestat on acute pancreatitis (AP) in a rat model. "
01/01/1998 - "The white blood cell count was markedly reduced in response to the induction of pancreatitis, and was decreased further by the septic attack, irrespective of the administration of ONO-5046, although the count increased again in the ONO group. "
11/01/2012 - "Potential of sivelestat in protection against severe acute pancreatitis-associated lung injury in rats."
12/01/2013 - "Protective effects of sivelestat in a caerulein-induced rat acute pancreatitis model."
01/01/1998 - "Therefore, we examined the therapeutic effect of a specific synthetic inhibitor of PMN elastase (ONO-5046: Ono Pharmaceuticals, Osaka, Japan) on the lung, liver, and kidney, as well as pancreas, in severe hemorrhagic pancreatitis in dogs. "
10/01/2010 - "The authors examined the efficacy of sivelestat in combination with a fluoroquinolone in a Legionella pneumophila pneumonia mouse model. "
10/01/2008 - "This study suggested the possibility that early administration of sivelestat may improve the ALI survival rate in severe pneumonia."
12/01/2014 - "We hypothesized that pretreatment with sivelestat therapy could attenuate ventilator-induced lung injury (VILI) and lung inflammation in a rat model. "
10/01/2008 - "We investigated the patients' background, pneumonia severity score, the days from diagnosis of systemic inflammatory response syndrome (SIRS) to sivelestat administration, P/F ratio, SIRS score, and compared two groups: those who survived and those who died. "
03/01/2007 - "Cell count and histopathological analysis indicated that sivelestat prevented the progression of lung inflammation, such as alveolar neutrophil infiltration and hemorrhage. "
|1.||Leukocyte Elastase (Neutrophil Elastase)
|3.||Taurocholic Acid (Sodium Taurocholate)
|4.||ONO 5046 (sivelestat)
|5.||Anti-Bacterial Agents (Antibiotics)
|9.||Interleukin-6 (Interleukin 6)
|1.||Artificial Respiration (Mechanical Ventilation)
|2.||Mechanical Ventilators (Ventilator)
|4.||Lymph Node Excision (Lymph Node Dissection)
|5.||Cardiopulmonary Bypass (Heart-Lung Bypass)